Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
The review found no eligible studies for this question.